Leukemia-differentiating activity expressed by the human melanoma cell line LD-1

Michael B. Lilly, Andrew Kraft

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We have identified a leukemia-differentiating activity (LDA) in medium conditioned by the LD-1 melanoma, a G-CSF secreting human tumor line. Partially-purified LDA induces HL-60 cells to produce superoxide, become phagocytic, and to develop macrophage-like morphology and surface markers. The LDA markedly suppresses clonal growth in agar of HL-60 cells, and cells of the human myeloid leukemia lines PBL 985 and K562, but does not suppress clonal growth of the B-lymphoblast lines Raji and Daudi. The molecular weight of this material is approx. 40,000 daltons. It can be separated from the bulk of the colony stimulating activity on phenyl sepharose chromatography. The LDA is not neutralized by antibodies to G-CSF, GM-CSF, IFNα, IFNγ, TNF, urokinase, and tissue plasminogen activator, and is not inhibited by preincubation with aprotinin. The LDA in conditioned medium may be different from previously described differentiating factors, and may represent an additional class of human growth regulators.

Original languageEnglish (US)
Pages (from-to)217-225
Number of pages9
JournalLeukemia Research
Volume12
Issue number3
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Human Activities
Melanoma
Leukemia
Cell Line
HL-60 Cells
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Conditioned Culture Medium
Growth
Agarose Chromatography
Aprotinin
Myeloid Leukemia
Urokinase-Type Plasminogen Activator
Tissue Plasminogen Activator
Superoxides
Agar
Molecular Weight
Macrophages
Antibodies
Neoplasms

Keywords

  • differentiation
  • HL-60
  • Leukemia
  • melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Leukemia-differentiating activity expressed by the human melanoma cell line LD-1. / Lilly, Michael B.; Kraft, Andrew.

In: Leukemia Research, Vol. 12, No. 3, 1988, p. 217-225.

Research output: Contribution to journalArticle

@article{910cc0576edf49a9b6675c66ce9331d6,
title = "Leukemia-differentiating activity expressed by the human melanoma cell line LD-1",
abstract = "We have identified a leukemia-differentiating activity (LDA) in medium conditioned by the LD-1 melanoma, a G-CSF secreting human tumor line. Partially-purified LDA induces HL-60 cells to produce superoxide, become phagocytic, and to develop macrophage-like morphology and surface markers. The LDA markedly suppresses clonal growth in agar of HL-60 cells, and cells of the human myeloid leukemia lines PBL 985 and K562, but does not suppress clonal growth of the B-lymphoblast lines Raji and Daudi. The molecular weight of this material is approx. 40,000 daltons. It can be separated from the bulk of the colony stimulating activity on phenyl sepharose chromatography. The LDA is not neutralized by antibodies to G-CSF, GM-CSF, IFNα, IFNγ, TNF, urokinase, and tissue plasminogen activator, and is not inhibited by preincubation with aprotinin. The LDA in conditioned medium may be different from previously described differentiating factors, and may represent an additional class of human growth regulators.",
keywords = "differentiation, HL-60, Leukemia, melanoma",
author = "Lilly, {Michael B.} and Andrew Kraft",
year = "1988",
doi = "10.1016/0145-2126(88)90139-7",
language = "English (US)",
volume = "12",
pages = "217--225",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Leukemia-differentiating activity expressed by the human melanoma cell line LD-1

AU - Lilly, Michael B.

AU - Kraft, Andrew

PY - 1988

Y1 - 1988

N2 - We have identified a leukemia-differentiating activity (LDA) in medium conditioned by the LD-1 melanoma, a G-CSF secreting human tumor line. Partially-purified LDA induces HL-60 cells to produce superoxide, become phagocytic, and to develop macrophage-like morphology and surface markers. The LDA markedly suppresses clonal growth in agar of HL-60 cells, and cells of the human myeloid leukemia lines PBL 985 and K562, but does not suppress clonal growth of the B-lymphoblast lines Raji and Daudi. The molecular weight of this material is approx. 40,000 daltons. It can be separated from the bulk of the colony stimulating activity on phenyl sepharose chromatography. The LDA is not neutralized by antibodies to G-CSF, GM-CSF, IFNα, IFNγ, TNF, urokinase, and tissue plasminogen activator, and is not inhibited by preincubation with aprotinin. The LDA in conditioned medium may be different from previously described differentiating factors, and may represent an additional class of human growth regulators.

AB - We have identified a leukemia-differentiating activity (LDA) in medium conditioned by the LD-1 melanoma, a G-CSF secreting human tumor line. Partially-purified LDA induces HL-60 cells to produce superoxide, become phagocytic, and to develop macrophage-like morphology and surface markers. The LDA markedly suppresses clonal growth in agar of HL-60 cells, and cells of the human myeloid leukemia lines PBL 985 and K562, but does not suppress clonal growth of the B-lymphoblast lines Raji and Daudi. The molecular weight of this material is approx. 40,000 daltons. It can be separated from the bulk of the colony stimulating activity on phenyl sepharose chromatography. The LDA is not neutralized by antibodies to G-CSF, GM-CSF, IFNα, IFNγ, TNF, urokinase, and tissue plasminogen activator, and is not inhibited by preincubation with aprotinin. The LDA in conditioned medium may be different from previously described differentiating factors, and may represent an additional class of human growth regulators.

KW - differentiation

KW - HL-60

KW - Leukemia

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=0023952344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023952344&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(88)90139-7

DO - 10.1016/0145-2126(88)90139-7

M3 - Article

C2 - 3163398

AN - SCOPUS:0023952344

VL - 12

SP - 217

EP - 225

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -